antonio-guillem-shutterstock-com-2

Antonio Guillem / Shutterstock.com

21 October 2015Americas

PTAB deals Bass another blow

The Patent Trial and Appeal Board (PTAB) has rejected another inter partes review (IPR) petition filed by hedge fund manager Kyle Bass’s organisation the Coalition for Affordable Drugs.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Kyle Bass tastes second success at the PTAB

27 October 2015 Hedge fund manager Kyle Bass and his Coalition for Affordable Drugs have tasted success at the Patent Trial and Appeal Board for the second time in a month after it agreed to institute an inter partes review of a patent covering a drug owned by NPS Pharmaceuticals.

Bass set for first IPR trial as Shire petition proceeds

9 October 2015 Hedge fund manger Kyle Bass has secured his first inter partes review trial after the Patent Trial and Appeal Board instituted a challenge against a patent owned by biopharmaceutical company Shire.

Bass suffers another IPR setback

3 September 2015 Hedge fund manager Kyle Bass’s Coalition for Affordable Drugs has suffered another setback in its bid to knock out allegedly spurious patents after the US Patent and Trademark Office declined to institute an inter partes review of a patent owned by Biogen.

More on this story

Kyle Bass tastes second success at the PTAB

27 October 2015 Hedge fund manager Kyle Bass and his Coalition for Affordable Drugs have tasted success at the Patent Trial and Appeal Board for the second time in a month after it agreed to institute an inter partes review of a patent covering a drug owned by NPS Pharmaceuticals.

Bass set for first IPR trial as Shire petition proceeds

9 October 2015 Hedge fund manger Kyle Bass has secured his first inter partes review trial after the Patent Trial and Appeal Board instituted a challenge against a patent owned by biopharmaceutical company Shire.

Bass suffers another IPR setback

3 September 2015 Hedge fund manager Kyle Bass’s Coalition for Affordable Drugs has suffered another setback in its bid to knock out allegedly spurious patents after the US Patent and Trademark Office declined to institute an inter partes review of a patent owned by Biogen.

More on this story

Kyle Bass tastes second success at the PTAB

27 October 2015 Hedge fund manager Kyle Bass and his Coalition for Affordable Drugs have tasted success at the Patent Trial and Appeal Board for the second time in a month after it agreed to institute an inter partes review of a patent covering a drug owned by NPS Pharmaceuticals.

Bass set for first IPR trial as Shire petition proceeds

9 October 2015 Hedge fund manger Kyle Bass has secured his first inter partes review trial after the Patent Trial and Appeal Board instituted a challenge against a patent owned by biopharmaceutical company Shire.

Bass suffers another IPR setback

3 September 2015 Hedge fund manager Kyle Bass’s Coalition for Affordable Drugs has suffered another setback in its bid to knock out allegedly spurious patents after the US Patent and Trademark Office declined to institute an inter partes review of a patent owned by Biogen.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Lord Justice Birss to become chancellor of the High Court

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?